Clinical Trial · NCT00588276

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Overview

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor. Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Phase 1

Contacts

Heiko Schöder, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00588276

Drug / Compound

Iodo-azomycin galactopyranoside

Isotope(s):

Target(s):

Hypoxia

Ligand Class: Small Molecules

Eligibility

Inclusion

KPS \>70%.
Patients must have locally advanced cancer as determined by currently accepted diagnostic work-up, including CT/MR/US.

Exclusion

Patients who cannot tolerate being in the PET scanner for the duration of the study.
Patients will be excluded from the study if they fulfill any of the following criteria:
Patients who are pregnant or lactating.